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The phosphatidylinositol 3 kinase (PI3K) pathway regulates fundamental cellular processes such as metabolism, proliferation, and sur-
vival. A central component in this pathway is the p85a regulatory subunit, encoded by PIK3R1. Using whole-exome sequencing, we
identified a heterozygous PIK3R1 mutation (c.1945C>T [p.Arg649Trp]) in two unrelated families affected by partial lipodystrophy,
low body mass index, short stature, progeroid face, and Rieger anomaly (SHORT syndrome). This mutation led to impaired interaction
between p85a and IRS-1 and reduced AKT-mediated insulin signaling in fibroblasts from affected subjects and in reconstituted Pik3r1-
knockout preadipocytes. Normal PI3K activity is critical for adipose differentiation and insulin signaling; the mutated PIK3R1 therefore
provides a unique link among lipodystrophy, growth, and insulin signaling.The phosphatidylinositol 3 kinase (PI3K) signaling path-
way is central to the action of many hormones and growth
factors, including insulin,1–3 and is essential for differenti-
ation of preadipocytes to adipocytes.4–6 Binding of insulin
to its receptor leads to intrinsic activation of tyrosine
kinase and phosphorylation of insulin-receptor substrates
(IRSs) 1 and 2. Phosphorylated IRSs then bind to the regu-
latory subunit of PI3K, p85a, which is encoded by PIK3R1
(MIM 171833). This results in activation of the p110 cata-
lytic subunit (encoded by PIK3CA [MIM 171834]) and pro-
duction of phosphatidylinositol 3,4,5-triphosphate (PIP3),
which in turn activates its major downstream target, AKT.5
Germline mutations in genes encoding components of the
PI3K signaling pathway have been linked to congenital dis-
eases characterized by disturbances in metabolism and
cellular growth. Thus, mutations in PTEN (MIM 601728)
are associated with cancer predisposition, insulin sensi-
tivity, and obesity,7 whereas activating AKT2 (MIM
164731) mutations cause a syndrome of hypoglycemia
and asymmetrical growth.8 Furthermore, germline muta-
tions resulting in gain of function of AKT3 (MIM
611223), PIK3R2 (MIM 603157), and PIK3CA cause disor-
ders characterized by overgrowth (megalencephaly-poly-
microgyria-polydactyly-hydrocephalus syndrome [MIM
603387]).9,10 In addition, somatic mutations of various
genes encoding components within this pathway, in-
cluding PIK3R1, PIK3CA, and AKT3, have been associated
with cancer development.10
We investigated two independent families (Table 1)
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also displaying partial lipodystrophy, low body mass
index (BMI), and a progeroid face. The study subjects pro-
vided written informed consent, and the regional ethics
committee approved the study. Statistical significance
was calculated with SPSS software and a Mann-Whitney
U nonparametric test comparing affected subjects and con-
trols. In family 1,11 four affected subjects in three genera-
tions had infancy-onset partial lipodystrophy, low BMI,
and dysmorphic features, including a progeroid face (Fig-
ures 1A and 1B and Table S1, available online). Affected
subjects had low birth weight, short stature, teething delay,
and Rieger anomaly, but no joint hyperextensibility. Dia-
betes developed between 22 and 55 years of age. Available
family members were followed up 38 years after the initial
description (Table 1). Subjects II-2 and III-2 were treated
with insulin, had poor metabolic control, and were very
lean (BMI 15.1 and 17.7 kg/m2, respectively). We obtained
blood samples after an overnight fast and measured serum
levels of lipids, cholesterols, and leptins, which were
within the normal range, whereas adiponectin levels
were in the upper limits of the normal range (Table 1).
Computed-tomography (CT) scans revealed extremely
scarce amounts of intra-abdominal and subcutaneous fat
in the flanks and slightly scarce subcutaneous fat in the
buttocks and thighs (Figure 2). There was no hepatic
steatosis.
In family 2,12 two affected subjects with strikingly
similar features to those of affected individuals in family 1
had infancy-onset partial lipodystrophy, low BMI, and pro-
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Table 1. Clinical and Biochemical Characteristics
Characteristic
Family 1 Family 2 Controlsa
II-1 II-2 II-3 III-1 III-2 II-1 III-1 III-2 n ¼ 16
Genotype NM NM NN NN NM NM NN NM NN
Gender female female male male male female male male 7 males and 9 females
Current age (years) deceased 79 65 45 42 53 20 15 38 5 9
BMI (kg/m2)b 22.5 15.1 25.0 NA 17.7 17.1 NA 13.9 21.5 5 1.7
Partial lipodystrophyc yes yes no no yes yes no yes no
Stature (cm) short (152) short (152) tall (192) normal short (163) short (153) normal short (161) normal (175 5 10)
Progeroid faced yes yes no no yes yes no yes no
Rieger anomaly yes yes no no yes yes no yes no
Diabetes yes yes yes no yes no no no no
Insulin treatment
(U/kg/day)
NA 1.4 varies no 1.6 no no no no
Vascular complications NA microalbuminuria,
neuropathy
yes no no no no no no
Fasting glucose
(4.0–6.0 mmol/l)e
5.1 12.1 14.1 NA 23.2 5.7 5.0 5.5 5.0 5 0.3
HbA1c (4.0%–6.4%) NA 9.9 10.7 NA 10.6 5.5 5.0 5.8 5.1 5 0.3
Total cholesterol
(3.9–7.8 mmol/l)
NA 5.5 4.6 NA 6.2 5.0 2.8 2.7 4.6 5 0.9
HDL cholesterol
(0.8–2.1 mmol/l)
NA 2.0 1.0 NA 1.5 2.2 1.1 1.5 1.9 5 0.6
LDL cholesterol
(1.8–5.7 mmol/l)
NA 3.4 3.2 NA 4.4 2.7 1.5 0.9 2.8 5 0.8
Triglycerides
(0.45–2.60 mmol/l)
NA 0.93 1.46 NA 1.46 0.98 0.80 0.68 0.7 5 0.2
Leptin (pmol/l)f NA 285 NA NA 389 1,121 68 61 138 5 36 (males) and
388 5 248 (females)
Adiponectin
(150–746 nmol/l)
NA 560 NA NA 469 491 439 307 361 5 174
The following abbreviations are used: NN, normal PIK3R1 genotype; NM, heterozygous PIK3R1 mutation c.1945C>T (p.Arg649Trp); NA, not available or not
applicable; HDL, high-density lipoprotein; and LDL, low-density lipoprotein.
aWe recruited BMI and age-matched controls from the staff at the Haukeland University Hospital.
bReference interval is 18–25 kg/m2.
cMainly affecting the face, flanks, and buttocks.
dMidface hypoplasia, wide and deep-set eyes, triangular face, and hypotrichosis.
eTo convert the values for glucose into mg/dl, multiply by 18.056.
fReference values are <465 pmol/l for males and <930 pmol/l for females.They had low birth weight, short stature, teething delay,
and Rieger anomaly, but no joint hyperextensibility. The
mother exhibited impaired glucose tolerance and mildly
elevated postprandial serum insulin. At the follow-up ex-
amination, subjects II-1 and III-2 had normal fasting
glucose and A1c values (Table 1). Serum lipids were within
the normal range, whereas adiponectin levels were in the
upper limits of the normal range (Table 1).
To establish the genetic cause of the disease, we per-
formed whole-exome sequencing of DNA from two
affected members (subjects II-1 and III-2) and one unaf-
fected member (subject III-1) of family 1. Whole-exome
sequencing, read mapping, and variant calling were per-
formed as described in Johansson et al.13 On average, weThe Amobtained 393 median coverage, and 88% of the exome
was covered at least 83. We identified an average of
14,253 exonic variants per individual after initial quality
control (Table S2). We used a fully penetrant autosomal-
dominant model and removed variants that were synony-
mous, noncoding, or identified in 52 Norwegian control
exomes or that had an allele frequency > 0.5% in 1000
Genomes (Table S2). After filtering, 182 exonic variants
were classified as rare. Filtering based on an autosomal-
dominant model reduced the number of variants to 22
(Table S3). We searched for direct or indirect associations
between our 22 candidates and 12 genes involved in insu-
lin signaling or lipodystrophy by performing a protein-
based network analysis (STRING). Only one candidateerican Journal of Human Genetics 93, 150–157, July 11, 2013 151
Figure 1. Pedigrees and Photos of
Affected Family Members
(A) Pedigrees of Norwegian family 1 and
German family 2. Filled symbols represent
affected family members, and open sym-
bols represent healthy individuals. DNA
from subject I-1 of family 1 was unavailable
for testing. The five other affected family
members were investigated and had the
mutation. Healthy subjects II-3 and III-1
of family 1 and subject III-1 of family 2
did not have the mutation. Circular sym-
bols represent females, and squares repre-
sent males. Arrows represent the probands
of each family. Stars indicate those individ-
uals from whom DNA was available.
(B) The photos reveal the key clinical signs.
Partial lipodystrophy is especially notice-
able in the face and the buttocks, and dys-
morphic features, including a progeroid
face with hypotrichosis (thin hair), frontal
bossing, wide and deep-set eyes, thin ala
nasi, a beaked nose, downturned lateral
corners of the mouth, and large ears, are
evident. Red arrows point to the typical fea-
tures. Photos are printed with permission
from John Wiley & Sons11 and Wolters
Kluwer Health.12gene, PIK3R1, clustered directly with insulin signaling
genes (PIK3CA, IRS1, IRS2, and INSR) and indirectly with
lipodystrophy genes (LMNA, BSCL2, AGPAT2, and PPARG)
(Figure S1). PIK3R1 had the heterozygous mutation
c.1945C>T (RefSeq accession number NM_181523.2), pre-
dicted to cause the substitution of arginine with trypto-
phan at amino acid position 649 (p.Arg649Trp) (RefSeq
NP_852664.1).
Sanger resequencing (Figure S2A and S2B) confirmed
that all affected members, but not the healthy members
(subjects II-3 and III-1), of family 1 carried the
c.1945C>T mutation. To exclude that this mutation was
common, we sequenced 340 Norwegian controls and
found that none of them carried the mutation. Amplifica-
tion of genomic DNA was carried out with primers
50-TTTGTCCTGGGAGGTTGCACTGGA-30 and 50-AAGG
CAGGCACTGCCACTTCCAT-30, yielding a PCR product
of 692 bp. We performed Sanger sequencing with the
same primers.
To investigate whether the mutant allele was tran-
scribed, we extracted RNA from cultured skin fibroblasts
with the RNeasy Kit (QIAGEN) and subsequently per-152 The American Journal of Human Genetics 93, 150–157, July 11, 2013formed cDNA synthesis (OneStep
RT-PCR, QIAGEN). A PCR product of
189 bp was amplified from the cDNA
with primers 50-AACACTGAACAATAT
TCACTGGTGG-30 and 50-TTCGCC
GTCCACTACAGAGC-30. Sanger se-
quencing was then performed with
the same primers on an ABI 3730
capillary sequencer (Applied Bio-
systems). Sequencing the PIK3R1cDNA isolated from fibroblasts confirmed that themutated
allele was transcribed (Figure S2B).
PIK3R1 encodes the PI3K p85a regulatory subunit,
which binds to the catalytic subunit p110 to form the
holoenzyme.14 The arginine residue at position 649 is
highly conserved. This amino acid is located in the Src
homology 2 (SH2) domain and is predicted to be involved
in direct binding to phosphorylated substrates including
receptor tyrosine kinases and adaptor proteins, such as
IRS-1 (Figures 3A and 3B). The mutation (c.1945C>T)
was scored by four different bioinformatics programs as
follows: PolyPhen-2, ‘‘probably damaging’’ (HumDiv score
1.000, HumVar score 1.000); SIFT, ‘‘damaging’’ (0.00);
Mutation Taster, ‘‘moderately radical’’ (by Grantham
Matrix, 101); and Align GVGD, ‘‘less likely’’ (class C0).
Sanger sequencing of DNA from two affected members
of family 2 demonstrated an identical PIK3R1 mutation
to that of family 1. The mutation was a C>T transition
occurring in the context of a CpG dinucleotide. CpGs are
potential methylation sites and, as such, are susceptible
to mutations because a methylated cytosine can sponta-
neously deaminate to thymine. This might explain the
Figure 2. CT Scans
Coronal reconstruction of contrast-enhanced CT scans of the
abdomen and proximal lower extremities of subject III-2 of family
1 (B) and a 79-year-old healthy female control (A). In the affected
person (B), the amount of subcutaneous fat (arrows) is strikingly
sparse in the upper abdomen and lower thorax (closed arrows),
whereas it seems normal in the buttocks and thighs (filled arrows).
In the control (A), there is proportional distribution of subcutane-
ous fat (arrows) in the thorax, abdomen, and pelvis. The affected
individual had normal liver attenuation (62 versus 8 Hounsfield
units in a subject with fatty liver), indicating no signs of hepatic
steatosis (not shown). The CT scans were performed according to
standard procedures.recurrent nature of the PIK3R1mutation reported here. We
performed Genome-Wide Human SNP Array 6.0 (Affyme-
trix) genotyping of both probands and their affected par-
ents (child-parent duos) and excluded a recent common
ancestry of the families by PLINK analysis. We also used
SNPs in the PIK3R1 region to search for contrary homozy-
gosity between the two families. This analysis allowed us
to confidently exclude sharing for all but a 41 kb region
in which all SNPs surrounding the mutation were uninfor-
mative: 67,573,663–67,615,528 bp on chromosome 5
(Human Genome Database build 19; the mutation is
located at 67,592,129). Haplotype reconstruction in the
region surrounding PIK3R1 showed that the mutations
reside on two different haplotype backgrounds (Figure S4).
Therefore, they stem from two independent mutational
events.
To understand the functional role of the mutation, we
made a structural model (PyMOL) of the C-terminal SH2
domain of p85a with arginine (normal) and tryptophan
(substituted) residues at position 649 in the phosphopep-
tide binding pocket in the presence of a platelet-derived
growth-factor-receptor phosphopeptide (Figures 3C and
3D). The normal arginine residue participates in a bivalent
interaction (2.7 and 2.8 A˚) with the oxygen atoms of the
phosphotyrosine residue, leading to enhanced contact
with the phosphopeptide within the binding pocket. The
altered tryptophan residue disrupts this interaction, which
could lead to reduced affinity for the phosphopeptide
(Figure 3D).
To test this hypothesis directly, we assessed PI3K activa-
tion and downstream insulin signaling in fibroblasts pre-
pared from punch biopsies of the skin from a normal
(subject II-3) and an affected (subject II-2) family member.The AmHuman primary fibroblasts were cultured in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with
10% fetal bovine serum (FBS), penicillin, and streptomycin
(Life Technologies). Cells were serum starved in DMEM
supplemented with 0.1% BSA for 3 hr and treated in the
absence or presence of 10 nM insulin (Sigma Aldrich) for
the indicated time points. Cells were lysed with 13 RIPA
lysis buffer (EMD Millipore), and lysates were subjected
to SDS-PAGE and subsequently immunoblotted with the
indicated antibodies. For PI3K-activation assays, immuno-
precipitations with the indicated antibodies were per-
formed overnight in buffer A containing 25 mM Tris-HCl
(pH 7.4), 2 mM Na3VO4, 10 mM NaF, 10 mM Na4P2O7,
1 mM EGTA, 1 mM EDTA, and 1% Nonidet P-40 supple-
mented with protease and phosphatase inhibitor cocktails
(Sigma Aldrich). Immune complexes were captured by
incubation with Protein A/G Plus Agarose (Santa Cruz
Biotechnology) for 1 hr at 4C. Immunoprecipitates were
subsequently washed three times in buffer A containing
500 mM NaCl and two times in PI3K reaction buffer
(20 mM Tris-HCl [pH 7.4], 100 mM NaCl, and 0.5 mM
EGTA) and suspended in 50 ml of PI3K reaction buffer
containing 0.1 mg/ml phosphatidylinositol (Avanti Polar
Lipids). The reactions were performed for 30 min at room
temperature, and phosphorylated lipids were separated
by thin-layer chromatography as described.15
In normal fibroblasts, insulin stimulation led to a robust
~4-fold increase in phosphotyrosine-associated PI3K activ-
ity, whereas in the mutant fibroblasts, only a ~2-fold in-
crease was observed (Figure 4A). Analysis of PI3K activity
in IRS-1 immunoprecipitates revealed a parallel reduction
in insulin-stimulated activity in mutant fibroblasts,
although this did not quite reach statistical significance
(Figure 4B). The observed trend for a reduction in IRS-1-
associated PI3K activity was not due to decreased levels
of p85a or efficiency of IRS-1 immunoprecipitation in
mutant fibroblasts (Figure S3A and S3B). In normal fibro-
blasts, insulin stimulation led to a robust increase in the
activation of downstream effectors of the PI3K pathway,
including AKT and GSK-3b (Figure 4C). In contrast, insulin
stimulation of fibroblasts from affected individuals re-
vealed that phosphorylation of AKT and GSK-3b was 53%
and 12% lower, respectively, than that of normal fibro-
blasts. This defect in PI3K-dependent signaling was not
due to a decrease in the protein levels of components in
this pathway, given that levels of p85a, p110, and GSK-
3b were unaltered in mutant fibroblasts.
To further explore the impact of the PIK3R1 mutation,
we reconstituted preadipocytes made deficient for both
p85a and p85b by genetic knockout (controls)16 with
constructs for Arg649 (normal) or Trp649 (substitution)
p85a by retroviral-mediated gene transduction. PIK3R1
mutation c.1945C>T was introduced into a human p85a
cDNA clone (Thermo Scientific) with the use of the
QuickChange Lightening Site-Directed Mutagenesis Kit
(Agilent Technologies). Resultant clones were sequenced
for verification that the desired mutation had beenerican Journal of Human Genetics 93, 150–157, July 11, 2013 153
Figure 3. Overview of the p85 Protein
with the p.Arg649Trp Substitution and
SH2 Sequences of Various Proteins
Related to p85
(A) Schematic illustration of p85a, the
different domains, and the position of
the p.Arg649Trp substitution.
(B) Multiple-sequence alignment of SH2
domains from the indicated human
proteins was performed with the Clustal
Omega sequence-alignment tool and
demonstrated absolute conservation of
the arginine residue (red color).
(C and D) Illustration that the
p.Arg649Trp-containing protein impairs
binding with the phosphotyrosine phos-
phate moiety. The panels show the sub-
strate-binding pocket of the p85a SH2
domain (Protein Data Bank ID 1H90)
with important residues for recognition
of the phosphotyrosine of a platelet-
derived growth-factor-receptor peptide
(pYMPMS).
(C) Arg649 in the wild-type (WT) p85a
SH2 domain is critical for the formation
of a bidentate interaction with the phos-
photyrosine phosphate. Represented by
black dotted lines, the distances between
the amino group of Arg649 and the phos-
phate group of pTyr are 2.7 A˚ (top) and
2.8 A˚ (bottom).
(D) Introduction of the p.Arg649Trp sub-
stitution causes loss of this key interaction
for substrate recognition.introduced and were subsequently cloned into the expres-
sion plasmid pBabe (Addgene). Reconstituted preadipo-
cytes were cultured in DMEM supplemented with 10%
FBS, penicillin, and streptomycin. Cells were serum starved
in DMEM supplemented with 0.1% BSA for 6 hr prior to in-
sulin stimulation. A PI3K assay was performed as described
above.
In the control cells lacking p85a and p85b, insulin eli-
cited a ~2-fold increase in phosphotyrosine-associated
PI3K activity at 5 and 10 min, indicating that some
signaling was possible through alternative pathways
(Figure 5A). As expected, this was augmented (~5-fold)
when reconstituted with normal p85a. Interestingly,
compared with pBabe controls, cells reconstituted with
Trp649 p85a showed a statistically significant (p < 0.05)
increase in basal activity, but this activity was not further
stimulated by insulin. Assessment of IRS-1-associated
activity revealed a significant (p < 0.01), insulin-depen-
dent increase in normal p85a-reconstituted cell lines, but
not in mutant cells (Figure 5B). Protein levels and immu-
noprecipitation efficiency were unaltered between the
cell lines examined either before or after insulin stimula-
tion, suggesting that any changes in IRS-1-associated activ-
ity were due to recruitment of the PI3K enzyme to IRS-1
(Figure S3C and S3D). Insulin-dependent activation of
downstream signals, such as AKT and GSK-3b, was barely
detectable in control knockout cells, whereas a robust acti-
vation was observed in normal p85a-reconstituted cells154 The American Journal of Human Genetics 93, 150–157, July 11, 2(Figures 5C and 5D). Again, compared to pBabe controls,
p85a-reconstituted cells showed a statistically significant
(p < 0.01), ~15-fold increase in basal activation, which
was not further stimulated by insulin; this is consistent
with results obtained for PI3K activation (Figure 5D).
There are multiple inherited clinical syndromes charac-
terized by lipodystrophy, i.e., abnormal distribution of sub-
cutaneous adipose tissue.17,18 Recessive forms can exhibit
generalized (Berardinelli-Seip syndrome [MIM 269700])
or partial loss of fat because of mutations in AGPAT2
(MIM 608594), BSCL2 (MIM 269700), CAV1 (MIM
601047), or PTRF (MIM 613327).19 Autosomal-dominant
forms are either generalized (Hutchinson-Gilford syn-
drome [MIM 176670]) as a result of LMNA mutations or
partial as a result of mutations in LMNA (Dunnigan syn-
drome [MIM 151660]), PPARG (MIM 604367), AKT2
(MIM 164731), or PLIN1 (MIM 613877). The disease mech-
anism of these lipodystrophies mainly involves distur-
bances in adipocyte differentiation and metabolism,
which is reflected in disturbances in serum levels of lipids,
leptin, and adiponectin.
The phenotype of our affected individuals seems
compatible with that of SHORT syndrome20, in which par-
tial lipodystrophy and facial dysmorphic features are part
of the phenotype as well. Some individuals also had insu-
lin resistance and/or diabetes. Certain features develop
relatively late in life. This, as well as other modifier genes,
might be the cause of the varying clinical presentation013
Figure 4. The p85a p.Arg649Trp Substitution Leads to Impaired
Insulin Signaling in Primary Human Fibroblasts
(A and B) PI3K activity was evaluated in (A) anti-phosphotyrosine
(PY) or (B) anti-IRS-1 immunoprecipitates in WT (normal) and
p.Arg649Trp human fibroblast cell lines before and after insulin
stimulation (10 mM) for 10 min. Data are expressed as a percent-
age of maximal stimulation, and p values were calculated by ordi-
nary one-way ANOVA testing (*p< 0.05, ***p< 0.001) (n¼ 3, data
are represented as mean5 SEM).
(C) Immunoblot analysis of lysates obtained from WT (normal)
and p.Arg649Trp fibroblasts before and after insulin stimulation
was performed with the indicated antibodies. Representative
immunoblots are shown.described in case reports. Until now, the genetic cause of
SHORT syndrome has been unknown. By finding that a
PIK3R1mutation, resulting in the substitution of an amino
acid in the SH2 domain, can cause this disease, we have
identified a cause of SHORT syndrome and a pathway asso-
ciated with partial lipodystrophy and growth retardation.
SH2 domains function as regulatory modules of intracel-
lular-signal-transduction pathways by virtue of their high-The Amaffinity interaction with tyrosine-phosphorylated pep-
tides.21,22 The majority of disease-causing alterations
of the SH2 domain affect highly conserved residues.23
Alignment of 120 human SH2 domains reveals that the
arginine residue at position 649 of p85a is conserved in
98% of these motifs. This arginine is predicted to partici-
pate in the recognition and binding of tyrosine-phosphor-
ylated substrates.24 When arginine is substituted with
tryptophan, structural modeling suggests that p85a loses
the interaction with its substrate and predicts a reduced
affinity for phosphopeptides. This is supported by our
studies in fibroblasts from individuals harboring the
PIK3R1 mutation; they showed a decrease in phosphotyr-
osine and IRS1-associated PI3K activity and a decrease in
downstream activation of AKT and GSK-3b in response
to insulin.
The p85a SH2 domains also negatively regulate basal
enzyme activity through allosteric, inhibitory interactions
with the catalytic subunit.25 This has been largely ascribed
to the N-terminal SH2 domain. However, reconstituted
preadipocytes with the altered p85a exhibited increased
basal activity of PI3K and a commensurate increase in
the activation of AKT and GSK-3b, supporting an impor-
tant role for the C-terminal SH2 domain in both basal
and insulin-stimulated activation of p110. In contrast to
individuals with many other lipodystrophy forms, the
individuals studied here exhibited no or very mild
insulin resistance and showed near normal levels of lipids,
leptin, and adiponectin. This might be due to insulin-
independent PI3K activation,26 explaining the elevated
basal PI3K levels found in mutant fibroblasts and in
preadipocytes reconstituted with Trp649 p85a. Loss of
adipose tissue in the affected individuals was confined
mainly to the face, flanks, and buttocks. The normal lep-
tin levels in our affected subjects indicate that leptin-
substitution therapy in this condition is not warranted.
Whether the observed short stature is due to impaired
insulin signaling remains to be explored. It is, however,
interesting to note that birth weights were low in affected
family members, and impaired insulin signaling might
therefore be the cause of the intrauterine and postnatal
growth retardation. Affected subjects displayed a spec-
trum of phenotypes that seem developmental in origin
and seem to be caused by impaired PI3K signaling rather
than by a secondary effect due to the development of
insulin resistance. In contrast to family 2, three affected
members of family 1 had diabetes. It is noteworthy that
family 1 subject II-3, who did not carry the mutation,
had diabetes and signs of insulin resistance. Thus, dia-
betes and possibly insulin resistance might at least partly
be due to other susceptibility factors present within this
family.
In conclusion, by identifying a genetic cause of SHORT
syndrome, we have revealed a mechanism for partial
lipodystrophy and growth retardation, adding expanded
possibilities for diagnosis and targeted treatment in these
diseases.erican Journal of Human Genetics 93, 150–157, July 11, 2013 155
Figure 5. Assessment of PI3K Pathway
Activation in WT and p.Arg649Trp-Recon-
stituted Cell Lines
(A and B) PI3K activity was measured in
(A) anti-phosphotyrosine or (B) anti-IRS-1
immunoprecipitates before and after insu-
lin stimulation (10 mM) for 10 min.
(C) Immunoblot analysis using the indi-
cated antibodies was performed on cell
lysates obtained from cell lines at the indi-
cated time points after insulin stimulation
(10 mM). Representative immunoblots are
shown.
(D) Quantification of AKT phosphoryla-
tion (S473) was performed with ImageJ.
Data are expressed as a percentage of
maximal stimulation, and p values were
calculated by ordinary one-way ANOVA
testing (*p < 0.05, **p < 0.01) (n ¼ 3,
data are represented as mean5 SEM).Supplemental Data
Supplemental Data include four figures and three tables and can
be found with this article online at http://www.cell.com/AJHG.Acknowledgments
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